Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MEREO BIOPHARMA (MREO : NSDQ)
 
 • Company Description   
Mereo BioPharma Group PLC is a biopharmaceutical company. It is focused on development and commercialization of therapeutics for patients with rare diseases. The company's product pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab which are in clinical stage. Mereo BioPharma Group PLC is based in London, United Kingdom.

Number of Employees: 49

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.44 Daily Weekly Monthly
20 Day Moving Average: 1,858,861 shares
Shares Outstanding: 116.98 (millions)
Market Capitalization: $51.09 (millions)
Beta: 2.00
52 Week High: $3.75
52 Week Low: $0.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -50.99% -46.30%
12 Week -66.92% -64.10%
Year To Date -72.71% -67.54%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE CAVENDISH PLACE FOURTH FLOOR
-
LONDON,X0 W1G0QF
GBR
ph: 44-33-3023-7300
fax: -
investors@mereobiopharma.com http://www.mereobiopharma.com
 
 • General Corporate Information   
Officers
Denise Scots-Knight - Chief Executive Officer and Director
Peter Fellner - Chairman
Christine Fox - Chief Financial Officer
Jeremy Bender - Director
Anders Ekblom - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 589492107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: 06/30/22
Share - Related Items
Shares Outstanding: 116.98
Most Recent Split Date: (:1)
Beta: 2.00
Market Capitalization: $51.09 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/30/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.42
Price/Cash Flow: 2.78
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - 7.92
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - 7.92
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - 39.06
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 1.03
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.16
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - 14.05
09/30/21 - -
 

Powered by Zacks Investment Research ©